Meridian Intelligence · Global Finance Intelligence

4 hr ago

MLYS

Mineralys outlines launch readiness ahead of December 22, 2026 PDUFA, with cash runway into 2028

Mineralys outlines launch readiness ahead of December 22, 2026 PDUFA, with cash runway into 2028. Market participants are assessing the implications for related…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

12 hr ago

IMNN

Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation

Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation. Market participants are asse…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

13 hr ago

APLM

Apollomics raises $10 million in private placement

Apollomics raises $10 million in private placement. Market participants are assessing the implications for related sectors and asset prices. Analysts note that …

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

15 hr ago

INTS

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3. Market participants are assessing th…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

16 hr ago

AUTL

Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months

Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months. Market participants are assessing the implications for related…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

16 hr ago

SLNPTGX

Morgan Stanley maintains Overweight rating on Silence Therapeutics

Morgan Stanley maintains Overweight rating on Silence Therapeutics. Market participants are assessing the implications for related sectors and asset prices. Ana…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

17 hr ago

WENNTLAPRPLSPCE

Short interest heatmap: Here are the most heavily bet-against stocks

Short interest heatmap: Here are the most heavily bet-against stocks. Market participants are assessing the implications for related sectors and asset prices. A…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

17 hr ago

BCAX

Bicara outlines mid-2027 interim analysis timeline as it initiates FORTIFI-FLEX and names a new CEO and CFO

Bicara outlines mid-2027 interim analysis timeline as it initiates FORTIFI-FLEX and names a new CEO and CFO. Market participants are assessing the implications …

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

17 hr ago

DMAC

DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger

DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger. Market participants are assessing the implications…

Meridian Intelligence View: Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.

Read full article →

Biotech

Mineralys outlines launch readiness ahead of December 22, 2026 PDUFA, with cash runway into 2028

Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation

Apollomics raises $10 million in private placement

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months

Morgan Stanley maintains Overweight rating on Silence Therapeutics

Short interest heatmap: Here are the most heavily bet-against stocks

Bicara outlines mid-2027 interim analysis timeline as it initiates FORTIFI-FLEX and names a new CEO and CFO

DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger

Biotech

Mineralys outlines launch readiness ahead of December 22, 2026 PDUFA, with cash runway into 2028

Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation

Apollomics raises $10 million in private placement

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months

Morgan Stanley maintains Overweight rating on Silence Therapeutics

Short interest heatmap: Here are the most heavily bet-against stocks

Bicara outlines mid-2027 interim analysis timeline as it initiates FORTIFI-FLEX and names a new CEO and CFO

DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger